Thymoglobuline plus basiliximab a mixed cocktail to start?

Area of Science:

• Nephrology
• Transplantation Immunology

Background:

• Dual induction therapy with thymoglobulin and basiliximab has been utilized since 2007 for kidney transplant recipients.
• A cohort of 235 patients received this
• induction cocktail
• over a 10-year period.

Discussion:

• Maintenance therapy involved calcineurin inhibitors (CNIs) combined with mycophenolate mofetil (MMF) or mammalian target of rapamycin inhibitors (mTORi).
• Results align with previous findings by Ciancio et al., supporting the efficacy of dual induction.
• The strategy potentially delays CNI introduction, mitigating delayed graft function and enhancing protection during targeted drug exposure.

Key Insights:

• Dual induction therapy demonstrated positive outcomes in patient and graft survival.
• A reduced incidence of acute rejection was observed.
• Renal function and post-transplant lymphoproliferative disorder rates were favorable.

Outlook:

• Further investigation into optimizing dual induction protocols is warranted.
• This approach may offer a valuable strategy for improving long-term kidney transplant outcomes.